

# Easton Pharmaceuticals, Inc.

A Wyoming Corporation

111 Brockhouse Road  
Toronto, Ontario M8W 2W8 Canada  
Telephone: 647-362-5700  
W:[www.eastonpharmaceuticalsinc.com](http://www.eastonpharmaceuticalsinc.com)  
E:[eastonpharma@protonmail.com](mailto:eastonpharma@protonmail.com)  
SIC: 2834

## Quarterly Report For the Period Ending June 30, 2019 (the "Reporting Period")

As of June 30, 2019, the number of shares outstanding of our Common Stock was:  
1,309,122,163

As of March 31, 2019, the number of shares outstanding of our Common Stock was:  
1,255,788,374

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes:  No:  (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes:  No:

---

## Easton Pharmaceuticals Inc. Financial Statements

### Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

Prepared by management without audit

#### 1) Name of the issuer and its predecessors (if any)

Easton Pharmaceuticals, Inc.

EASTON PHARMACEUTICALS, Inc. (the "Company") was initially formed as L.A.M. Pharmaceutical, Corp. (the "LLC") on July 24, 1998. From February 1, 1994 to July 24, 1998 the Company conducted its activities under the name RDN. In September 1998, the members of LLC, a Florida limited liability company, exchanged all of their interests in LLC for 6,000,000 shares of LAM Industries Inc's common stock. The stock exchange between the Company and the members of LLC is considered a recapitalization or reverse acquisition. Under reverse acquisition accounting, LLC was considered the acquirer for accounting and financial reporting purposes, and acquired the assets and assumed the liabilities of the Company. In 2009 the Company reorganized in the state of Delaware and changed its name to LAM Industries, Inc. On March 17, 2010 the Company and its shareholders again approved and implemented a name change from LAM Industries Inc. to Easton Pharmaceuticals, Inc. and subsequently registered with FINRA for a new stock symbol. The Company's stock symbol was changed from LAIC to EAPH. In August of 2012, the company approved and changed corporate domicile from the State of Delaware to the State of Wyoming.

The Company is currently active in the State of Wyoming.

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes:  No:

#### 2) Security Information

Trading Symbol: EAPH

Exact title and class of securities outstanding: Common

CUSIP: 92763N202

Par or stated value: \$0.0001

Total shares authorized: 3,000,000,000 as of: June 30, 2019

Total common shares outstanding: 1,309,122,163 as of: June 30, 2019

Number of shares in public float: 1,055,384,413 as of: June 30, 2019

Total number of shareholders of record: 94 as of: June 30, 2019

#### Transfer Agent

Name: Corporate Stock Transfer, Inc.

Phone: 1(303) 282-4800

Email: N/A

Is the Transfer Agent registered under the Exchange Act?\* Yes: X No:

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

# Easton Pharmaceuticals Inc. Financial Statements

## Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

Prepared by management without audit

None.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None.

### 3) Issuance History

#### A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Number of Shares outstanding as of January 1, 2016		Opening Balance:							
		Common: <u>932,728,571</u> Preferred: <u>0</u>							
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exempt or Regist Type?
<u>July 14, 2017</u>	<u>New Issuance</u>	<u>218,000,000</u>	<u>Common</u>	<u>\$0.03</u>	<u>No</u>	<u>iBliss Inc. / LongTran</u>	<u>Acquisition</u>	<u>Unrestricted</u>	<u>Exempt</u>
<u>August 22, 2018</u>	<u>New Issuance</u>	<u>60,000,000</u>	<u>Common</u>	<u>\$0.018</u>	<u>No</u>	<u>Alliance Venture Partners / Evan Karras</u>	<u>Employment</u>	<u>Unrestricted</u>	<u>Exempt</u>
<u>September 18, 2018</u>	<u>New Issuance</u>	<u>666,665</u>	<u>Common</u>	<u>\$0.013</u>	<u>No</u>	<u>Guilherme Gomes</u>	<u>Consulting</u>	<u>Restricted</u>	<u>Exempt</u>
<u>January 8, 2019</u>	<u>New Issuance</u>	<u>16,544,444</u>	<u>Common</u>	<u>\$0.01</u>	<u>Yes</u>	<u>CCI / Nicholas R. Salerno</u>	<u>Settlement of Debts</u>	<u>Unrestricted</u>	<u>Exempt</u>
<u>January 22, 2019</u>	<u>New Issuance</u>	<u>27,848,694</u>	<u>Common</u>	<u>\$0.0079</u>	<u>Yes</u>	<u>CCI / Nicholas R. Salerno</u>	<u>Settlement of Debts</u>	<u>Unrestricted</u>	<u>Exempt</u>
<u>April 1, 2019</u>	<u>New Issuance</u>	<u>53,333,789</u>	<u>Common</u>	<u>\$0.003</u>	<u>Yes</u>	<u>CCI / Nicholas R. Salerno</u>	<u>Settlement of Debts</u>	<u>Unrestricted</u>	<u>Exempt</u>
Shares Outstanding on June 30, 2019:		Ending Balance:							
		Common: <u>1,309,122,163</u> Preferred: <u>0</u>							

## Easton Pharmaceuticals Inc. Financial Statements

### Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

Prepared by management without audit

#### B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe any issuance of promissory notes, convertible notes or convertible debentures **in the past two completed fiscal years and any subsequent interim period.**

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder	Reason for Issuance (e.g. Loan, Service etc.)
<u>July 21, 2016</u>	<u>\$50,773</u>	<u>\$40,000</u>	<u>\$10,773</u>	<u>July 21, 2017</u>	<u>Conversion price of \$0.001 per common share</u>	<u>Robert Vivacqua</u>	<u>Loan</u>
<u>March 16, 2017</u>	<u>\$60,205</u>	<u>\$50,000</u>	<u>\$10,205</u>	<u>March 16, 2018</u>	<u>Conversion price of \$0.001 per common share</u>	<u>SEAS Industries Inc. / Robert Vivacqua</u>	<u>Loan</u>
<u>June 20, 2017</u>	<u>\$288,504</u>	<u>\$244,950</u>	<u>\$43,545</u>	<u>June 20, 2018</u>	<u>Conversion price of \$0.001 per common share</u>	<u>SEAS Industries Inc. / Robert Vivacqua</u>	<u>Loan</u>
<u>August 1, 2017</u>	<u>\$235,593</u>	<u>\$202,000</u>	<u>\$33,593</u>	<u>August 1, 2018</u>	<u>Conversion price of \$0.001 per common share</u>	<u>SEAS Industries Inc. / Robert Vivacqua</u>	<u>Loan</u>
<u>June 20, 2019</u>	<u>\$38,270</u>	<u>\$38,270</u>	<u>\$0</u>	<u>June 20, 2020</u>	<u>Conversion price of \$0.0005</u>	<u>2094588 Ontario Ltd./ Vince Demasi</u>	<u>Loan</u>
<u>June 20, 2019</u>	<u>\$38,270</u>	<u>\$38,270</u>	<u>\$0</u>	<u>June 20, 2020</u>	<u>Conversion price of \$0.0005</u>	<u>2450076 Ontario Inc. / Robert Vivacqua</u>	<u>Loan</u>

Use the space below to provide any additional details, including footnotes to the table above:

\_\_\_\_\_

#### 4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP  
 IFRS

B. The financial statements for this reporting period were prepared by:

Name: Evan Karras  
 Title: CEO  
 Relationship to Issuer: Officer & Director

# Easton Pharmaceuticals Inc. Financial Statements

## Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

Prepared by management without audit

### BALANCE SHEET

UNAUDITED	June 30 2019	June 30 2018
<b>ASSETS</b>		
<b>Current Assets</b>		
Cash and cash equivalents	\$ 148,395	\$ 5,020
Inventory	131,789	-
Due from director	-	-
<b>Total Current Assets</b>	<b>280,184</b>	<b>\$5,020</b>
<b>Long-Term Investments</b>		
1124123 Ontario Inc. (o/a Alliance Partners) – 50.00% ownership (Note 1)	1,206,326	1,024,625
<b>Other Assets</b>		
Prepaid Expense	510,958	777,588
Deposit on Real Estate (Note 2)	93,985	-
Equipment (Note 3)	6,980,065	-
<b>Intangible Assets</b>		
Gaming software (Note 4)	250,000	-
Licensing right (VagiSan (VS-Sense), AmnioSense from CommonSense, Biolyse Pharma)	1,402,588	625,000
Acquisition right (Note 5)	6,540,000	-
<b>Total Assets</b>	<b>17,264,106</b>	<b>2,432,233</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</b>		
<b>Current Liabilities</b>		
Accounts payable and accrued expenses	\$ 837,087	\$ 33,774
Bank overdraft	1,121	-
Salaries and wages payable	474,500	80,000
<b>Total Current Liabilities</b>	<b>1,312,708</b>	<b>113,774</b>
<b>Other Liabilities</b>		
Promissory note(s)	1,732,462	1,732,462
Other loans	6,726,855	573,640
Due to director(s)	141,574	51,222
<b>Total Liabilities</b>	<b>9,913,599</b>	<b>2,471,098</b>
<b>Stockholders' Equity (Deficit)</b>		
Preferred Stock		
Authorized: 20,000,000 preferred shares par value \$0.0001 each		
Issued: nil preferred shares	-	-
Common Stock		
Authorized: 3,000,000,000 common shares par value \$0.0001 each		
Issued: 1,309,122,163 common shares (1,309,122,163 as of June 30, 2019)	130,912	93,273
Additional paid-in capital	46,528,922	39,120,573
Accumulated deficit	(39,309,327)	(39,099,711)
<b>Total Stockholders' Equity (Deficit)</b>	<b>7,350,507</b>	<b>(38,865)</b>
<b>Total Liabilities and Stockholders' Equity</b>	<b>\$ 17,264,106</b>	<b>\$ 2,509,963</b>

The accompanying notes are an integral part of these unaudited financial statements.  
These unaudited financial statements have been prepared by management

# Easton Pharmaceuticals Inc. Financial Statements

## Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

Prepared by management without audit

### STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) for the period December 31, 2006 through June 30, 2019

UNAUDITED	Number of Shares	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total Stockholders' Equity (Deficit)
<b>Balance – December 31, 2006</b>	<b>38,421</b>	<b>\$ 4</b>	<b>\$ 35,148,993</b>	<b>\$ (35,588,313 )</b>	<b>\$ (439,316 )</b>
Net loss December 31, 2007	-	-	-	(150,106 )	(150,106 )
<b>Balance – December 31, 2007</b>	<b>38,421</b>	<b>\$ 4</b>	<b>\$ 35,148,993</b>	<b>\$ (35,738,419 )</b>	<b>\$ (589,422 )</b>
Common shares issued:					
-to settle promissory note	14,258,220	1,426	12,832	-	14,258
Capital contribution – accounts payable beyond statute of limitations	-	-	886,958	-	886,958
Net loss December 31, 2008	-	-	-	(621,643 )	(621,643 )
<b>Balance – December 31, 2008</b>	<b>14,296,641</b>	<b>\$ 1,430</b>	<b>\$ 36,048,783</b>	<b>\$ (36,360,062 )</b>	<b>\$ (309,849 )</b>
Common shares issued:					
-to acquire Viorra assets	36,000,000	3,600	-	-	3,600
-to acquire Ixora assets	8,000,000	800	545,345	-	546,145
-to settle promissory notes	28,516,356	2,851	47,149	-	50,000
Net loss December 31, 2009	-	-	-	(15,665 )	(15,665 )
<b>Balance – December 31, 2009</b>	<b>86,812,997</b>	<b>\$ 8,681</b>	<b>\$ 36,641,277</b>	<b>\$ (36,375,727 )</b>	<b>\$ 274,231</b>
Net loss December 31, 2010	-	-	-	(56,774 )	(56,774 )
<b>Balance – December 31, 2010</b>	<b>86,812,997</b>	<b>\$ 8,681</b>	<b>\$ 36,641,277</b>	<b>\$ (36,432,501 )</b>	<b>\$ 217,457</b>
Issued for consulting fees	1,000,000	100	24,900	-	25,000
Net loss December 31, 2011	-	-	-	(112,630 )	(112,630 )
<b>Balance – December 31, 2011</b>	<b>87,812,997</b>	<b>\$ 8,781</b>	<b>\$ 36,666,177</b>	<b>\$ (36,545,131 )</b>	<b>\$ 129,827</b>
Issued for consulting fees	40,000,000	4,000	196,000	-	200,000
Net loss December 31, 2012	-	-	-	(183,281 )	(183,281 )
<b>Balance – December 31, 2012</b>	<b>127,812,997</b>	<b>\$ 12,781</b>	<b>\$ 36,862,177</b>	<b>\$ (36,728,412 )</b>	<b>\$ 146,546</b>
Issued for financing cash received	231,900,000	23,190	322,049	-	345,239
Unrealized foreign exchange gain	-	-	8,949	-	8,949
Net loss December 31, 2013	-	-	-	(346,533 )	(346,533 )
<b>Balance – December 31, 2013</b>	<b>359,712,997</b>	<b>\$ 35,971</b>	<b>\$ 37,193,175</b>	<b>\$ (37,074,945 )</b>	<b>\$ 154,201</b>
Issued for financing cash received	140,287,003	14,029	682,971	-	697,000
Issued for debt	35,000,000	3,500	244,900	-	248,400
Issued for management fees payable	40,000,000	4,000	280,000	-	284,000
Issued for account payable	5,300,000	530	34,270	-	34,800
Issued for long term debt	31,428,571	3,143	106,857	-	110,000
Error correction	-	-	-	100,000	100,000
Net loss December 31, 2014	-	-	-	(360,848 )	(360,848 )
<b>Balance – December 31, 2014</b>	<b>611,728,571</b>	<b>\$ 61,173</b>	<b>\$ 38,542,173</b>	<b>\$ (37,335,793 )</b>	<b>\$ 1,267,553</b>
Issued To Medicated Markets	200,000,000	20,000	-	-	20,000
Issued for distribution agreement	5,000,000	500	-	-	500
Issued for director fees	60,000,000	6,000	294,000	-	300,000
Issued for consulting fees	6,000,000	600	39,400	-	40,000
Issued as BMV prepaid expense	50,000,000	5,000	245,000	-	250,000
Net loss December 31, 2015	-	-	-	(599,941 )	(599,941 )
<b>Balance – December 31, 2015</b>	<b>932,728,571</b>	<b>\$ 93,273</b>	<b>\$ 39,120,573</b>	<b>\$ (37,935,734 )</b>	<b>\$ 1,278,112</b>
Net loss December 31, 2016	-	-	-	(872,822)	(872,822)
<b>Balance – December 31, 2016</b>	<b>932,728,571</b>	<b>\$ 93,273</b>	<b>\$ 39,120,573</b>	<b>\$ (38,808,556 )</b>	<b>\$ 405,290</b>
Issued for iBliss per agreement	218,000,000	21,800	6,518,200	-	6,540,000
Net loss December 31, 2017	-	-	-	(245,279)	(245,279)
<b>Balance – December 31, 2017</b>	<b>1,150,728,571</b>	<b>\$ 115,073</b>	<b>\$ 45,638,773</b>	<b>\$ (39,053,835)</b>	<b>\$ 6,700,011</b>
Issued for consulting fees	60,000,000	6,000	594,000	-	600,000
Issued to reduce shareholder loan	666,665	67	4933	-	5,000
Net loss – December 31, 2018	-	-	-	(169,199)	(169,199)
<b>Balance – December 31, 2018</b>	<b>1,211,395,236</b>	<b>\$ 121,140</b>	<b>\$ 46,237,706</b>	<b>\$ (39,223,034)</b>	<b>\$ 7,135,812</b>
Issued for accounts payable	44,393,138	4,439	141,215	-	145,654
Net profit – March 31, 2019	-	-	-	7,878	7,878
<b>Balance – March 31, 2019</b>	<b>1,255,788,374</b>	<b>\$ 125,579</b>	<b>\$ 46,378,921</b>	<b>(39,215,156)</b>	<b>7,289,344</b>
Issued for accounts payable	53,333,789	5,333	150,001	-	155,334
Net loss – June 30, 2019	-	-	-	(94,171)	(94,171)
<b>Balance – June 30, 2019</b>	<b>1,309,122,163</b>	<b>\$ 130,912</b>	<b>\$ 46,528,922</b>	<b>(39,309,327)</b>	<b>7,350,507</b>

## Easton Pharmaceuticals Inc. Financial Statements

### Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

Prepared by management without audit

#### STATEMENT OF OPERATIONS

For the Quarter Ended June 30, 2019	2019	2018
<b>UNAUDITED</b>		
<b>Sales</b>		
Service revenue (note 6)	\$ 410,411	\$ 22,000
Cost of service revenue	307,692	13,020
Food processing revenue (note 7)	97,881	
Cost of food processing revenue	121,853	
<b>Gross Profit</b>	<b>78,747</b>	<b>8,980</b>
<b>Operating Expenses</b>		
Management fees	75,000	-
Subscription fees	1,500	1,196
Transfer agent	1,233	1,700
Professional fees	86,889	-
Marketing expense	796	
General and administrative expense	7,500	6,960
<b>Total Operating Expenses</b>	<b>172,918</b>	<b>9,856</b>
<b>Gain (Loss) Before Other Income (Expenses)</b>	<b>(94,171)</b>	<b>(876)</b>
<b>Other Income (Expenses)</b>		<b>(45,000)</b>
<b>Total Other Income (Expenses)</b>	<b>-</b>	<b>(45,000)</b>
<b>Net Gain (Loss) Before Taxes</b>	<b>-</b>	<b>-</b>
Income taxes	-	-
<b>Net Gain (Loss)</b>	<b>\$ (94,171)</b>	<b>\$ (45,876)</b>
<b>Loss per Common Share - Basic and Diluted</b>	<b>\$ 0.00</b>	<b>\$ 0.00</b>
<b>Weighted Average Number of Common Shares Outstanding:</b>		
<b>Basic and Diluted</b>	<b>1,309,122,163</b>	<b>1,150,728,571</b>

The accompanying notes are an integral part of these unaudited financial statements.  
These financial statements have been prepared by management without audit

## Easton Pharmaceuticals Inc. Financial Statements

### Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

Prepared by management without audit

#### STATEMENTS OF CASH FLOWS

For the Quarter ended March 31	2019	2018
<b>UNAUDITED</b>		
<b>Cash Flows from Operating Activities</b>		
Net Income (Loss)	\$ (94,171)	\$ (45,876)
Increase in accounts payable and accrued expenses	627,995	3,000
Prepaid expense	3,000	-
Operating expenses paid by director(s)	13,680	-
Non-cash settlement of debt (note 6)	212,501	-
<b>Net Cash Flows from Operating Activities</b>	<b>951,347</b>	<b>(42,876)</b>
<b>Cash Flows from Investing Activities</b>		
Deposit on real estate	(18,797)	-
<b>Net Cash Flows from Investing Activities</b>	<b>(18,797)</b>	<b>-</b>
<b>Cash Flows from Financing Activities</b>		
Bank overdraft	1,121	2,896
<b>Net Cash Flows from Financing Activities</b>	<b>1,121</b>	<b>2,896</b>
<b>Effect of foreign exchange on cash</b>	<b>-</b>	<b>-</b>
<b>Net Change in Cash and Cash Equivalents</b>	<b>933,671</b>	<b>(39,980)</b>
Cash and Cash Equivalents - Beginning of Year	192,452	-
<b>Cash and Cash Equivalents - End of Year</b>	<b>\$ 274,689</b>	<b>\$ -</b>
<b>NON-CASH INVESTING AND FINANCING ACTIVITIES</b>		
Stock issued to settle promissory notes payable	\$ 0	\$ 0
<b>SUPPLEMENTAL DISCLOSURE</b>		
Interest Paid	\$ 0	\$ 0
Income Taxes Paid	\$ 0	\$ 0
Common shares issued for assets	\$ 0	\$ 0

The accompanying notes are an integral part of these unaudited financial statements.  
These financial statements have been prepared by management without audit



**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

**NOTES TO FINANCIAL STATEMENTS**

Note 1: 1124123 Ontario Inc. owns 145 acres in Georgina, Ontario located at 6017 Smith Blvd. Easton owns 50% of 1124123's interest in the property.

Note 2: Easton has placed \$100,000 CAD deposit in trust for the purchase of 111 Brockhouse Rd. Toronto, Ontario which is where the Company currently operates its food processing company and maintains corporate offices. A further \$25,000 CAD deposit has been placed for the acquisition of 16399 Airport Rd., Toronto, Ontario for the purpose of creating a beverage bottling company for infused products.

Note 3: Easton acquired 100% of the assets of Supreme Sweets Inc. on April 24, 2019. The Fair Market Value of the equipment was appraised at \$9,119,500 CAD.

Note 4: Easton entered into an agreement in October 2018 to acquire a fully operational video slot game, as well as bingo game content. The games are currently being developed and they will be placed in operating casinos leading to daily revenue for Easton. The games are expected to be placed in casinos in Q3 of 2019.

Note 5: Easton had entered into an agreement for the acquisition of iBliss Inc. As a result of Easton's inability to fulfil its obligations as per the agreement and the declining stock price of Easton's common shares, the agreement was restructured.

Note 6: Easton has a service agreement to frame 150 homes in Whitby, Ontario and the Service revenue is a result of this agreement. The contract is ongoing with a further phase of homes commencing.

Note 7: Easton acquired 100% of Supreme Sweets Inc. on April 24, 2019 and operates a food processing company.

**Salaries and wages payable**

Salaries and Wages payable are \$474,500, as of June 30, 2019. The balance owing is unsecured, non-interest bearing and without fixed terms of repayments. They may be converted to shares of common stock.

**Due to related parties and other loans payable**

Amounts due to related parties and other loans payable are unsecured, bear no interest and are payable on demand. They may be converted to shares of common stock.

**Due to Director(s)**

The Director(s) paid operating expenses and deposits on real estate acquisitions on behalf of the Company in the amount of \$141,574. This includes prior periods as well as the Quarter Ended June 30, 2019.

**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

## **5. ISSUER'S BUSINESS, PRODUCTS AND SERVICES**

### **A. Description of Business Operations**

#### **Product and Market Overview**

EASTON PHARMACEUTICALS, Inc. is the owner and developer of a proprietary transdermal delivery technology that has been incorporated in a line of therapeutic OTC products (Viorra Delivery Matrix or "VDM") that management believes will be commercialized to transport various medicinal ingredients in vivo. The combination of the delivery technology and active ingredients together is intended to be developed and commercialized for marketing and sale on a global basis. Active ingredients include, or will include a combination of generally recognized as safe ("GRAS") additives, approved cosmetic ingredients or approved drugs (the combination of the VDM trans dermal delivery matrix and any drugs are not currently approved or cleared in any jurisdiction). The Company's products are currently in various stages of commercialization: basic research; proof of concept research; development; and, commercialization. Product commercialization is currently focused on the Company's product, "Viorra", an aid to the relief of female sexual arousal disorder (FSAD). Since 2009 the Company has not recognized material sales of Viorra or other VDM-based products to date.

In mid 2008 EASTON PHARMACEUTICALS abandoned and suspended any further research and development or commercialization efforts for products based on the L.A.M. Pharmaceutical's L.A.M. IPM™ technology. This asset was the basis of L.A.M. Pharmaceutical's IPM Wound Gel and delivery system, and other various L.A.M. Pharmaceutical's products. This technology involved the use of the L.A.M. Pharmaceutical's Ionic Polymer Matrix™ technology (L.A.M. IPM™) for the purpose of delivering, enhancing and sustaining the action of certain established therapeutic agents. EASTON PHARMACEUTICALS subsequently replaced the original delivery system in favor of the acquired Viorra proprietary delivery technology Viorra Delivery Matrix "VDM". In 2008 the prior EASTON PHARMACEUTICALS Board of Directors reviewed strategic alternatives regarding the L.A.M. IPM™ and its patented IPM Wound Gel assets including but not limited to sale, licensing, abandonment or future product development. In late 2008 and early 2009, EASTON PHARMACEUTICALS agreed to divest L.A.M. IPM™ and its patented IPM Wound Gel assets, and shortly thereafter acquired the remaining assets and know-how of Ixora Bio Medical Company Inc. ("IXORA") and Viorra Bio Medical Inc. ("VBMI") together with the VDM technologies and other assets. The Company believes the VDM delivery system can provide superior efficacy for the Company's current focus on topical FSAD, and other products.

Prior to the acquisition of VBMI and IXORA the Company's corporate objectives were to develop, market and license wound healing and the trans dermal delivery of drugs, therapeutic preparations and cosmetics for the prescription, over-the-counter and cosmetic markets, utilizing L.A.M. Pharmaceutical Ionic Polymer Matrix™ technology ("L.A.M. IPM™"). It was the Company's intention to seek out corporate alliances and co-marketing partnerships where other drugs and topical products could be enhanced by the L.A.M. IPM™ technology.

**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

Easton Pharmaceuticals intention was to acquire complementary products, technologies or companies by identifying and evaluating potential products and technologies developed by third parties that it believed would fit within the overall objective. Since incorporation in 1999 the Company raised approximately \$18 million for research and development to commercialize its main pipeline of products, specifically the L.A.M. IPM Wound Gel <sup>TM</sup>.

**Past and Present Product Development**

In December 1997, EASTON PHARMACEUTICALS granted an exclusive worldwide license to IXORA with rights granted for the marketing, sale and distribution of certain trans dermal treatments for male and female sexual dysfunction. EASTON PHARMACEUTICALS received licensing, milestone, and other fees and payments of approximately \$1,050,000 plus 2,025,000 common shares of IXORA; the consideration paid in shares of IXORA represented at that time 45% of the then outstanding share capital of IXORA.

Under terms of the then IXORA license agreement Easton Pharmaceuticals obligations were to protect and bear the cost of defending the corresponding patent rights and IXORA's obligations related to reimbursing LAM, or to directly pay for: identified and qualifying costs of research and development including clinical studies determined necessary to complete regulatory filings in the US and other jurisdictions and various regulatory agencies that regulate the marketing and sale of the products; and, cost related to patent procurement and maintenance costs of the underlying intellectual property. The agreement has a term of 99 years and the following termination provisions:

- Ixora fails to pay any money due under the contract, but only in the event that the amount due remains outstanding 60 days after receipt of written notice from us that the amount is due, or
- Either party becomes bankrupt or insolvent, or
- Either party fails to observe, perform or keep any of the material covenants, provisions, stipulations, representations and conditions contained in the contract and that the breach has not been cured within 60 days after receipt by the defaulting party of notice of such breach

Under the then terms of the licensing agreement IXORA is responsible for the manufacturing of the product, to ensure that the IPM matrix is manufactured in accordance with the Good Manufacturing Practices (GMP) and that the product is safe and performs to its specifications. Under the terms of the agreement EASTON PHARMACEUTICALS would have received the following royalties on sales under the agreement from IXORA:

- 9% of all net sales of licensed products approved by the FDA and for which the patent rights have not expired.
- 6.5% of all net sales of all licensed products which did not require FDA approval and for which the patent rights have not expired.
- 4.5% of all net sales of all licensed products for which the patent rights have expired or have been shown to be invalid.

**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

At the time of the acquisition of the IXORA assets by EASTON PHARMACEUTICALS and thereafter, EASTON PHARMACEUTICALS and IXORA confirm that the exclusive worldwide license granted IXORA remain valid, in full force and effect. On April 15, 2002, EASTON PHARMACEUTICALS obtained clearance from the United States Food and Drug Administration (“FDA”) of its Section 510(k) pre-market notification of intent (number K020325) to market its proprietary L.A.M. IPM Wound Gel™. Limited commercial sales of this product began in August 2002. The customer base was primarily derived from wound care professionals and centers, doctors, nurses, hospitals and individual sales through the Internet.

EASTON PHARMACEUTICALS subsequently hired consultants directly involved in the initial development of the L.A.M. IPM Wound Gel™ and who were directly responsible for obtaining its 510K approval by the FDA to complete the reformulation efforts. In 2006 the Company's then President Joseph Slechta passed away. This was deemed a material setback to the Company resulting in the loss of valuable relationships brought forward by Mr. Slechta. In the fall of 2008, the board of directors of EASTON PHARMACEUTICALS made the decision to divest itself of its L.A.M. IPM Wound Gel and transdermal delivery system.

On November 12, 2003 EASTON PHARMACEUTICALS entered into an exclusive distribution agreement with Verus S.A. de C.V. ("Verus") to distribute our L.A.M. IPM Wound Gel™ in several South American, Central American and Caribbean countries. Under the terms of the agreement the financial and other obligations of the parties were to commence when Verus receives marketing authorization from regulatory authorities in at least one of the countries and was to continue for at least one year from such date. The agreement term was extended, without a specified term on a non-exclusive basis upon the expiration of the initial term and was agreed to continue to be extended unless terminated by the delivery of notice, one party to the other with thirty days written notice. EASTON PHARMACEUTICALS had the right to terminate the agreement with Verus at any time. To date, EASTON PHARMACEUTICALS has not received any payments under this agreement. Consequently the Company made the decision to terminate the agreement and relationship with Verus.

On March 24, 2004, EASTON PHARMACEUTICALS received approval from the Chinese State Food and Drug Administration for the importation and sale of the L.A.M. IPM Wound Gel™ in the Peoples Republic of China. In 2004 EASTON PHARMACEUTICALS signed a three-year distribution agreement with China National Pharmaceutical Foreign Trade Corporation (“Sinopharm”). The agreement granted Sinopharm the exclusive distribution rights to market and sell L.A.M. IPM Wound Gel™ in China. Under the terms of this agreement the rights granted could be terminated by either party immediately upon giving written notice if certain performance criteria or financial obligations were not met. EASTON PHARMACEUTICALS did not receive any payments from Sinopharm. Under terms of the agreement EASTON PHARMACEUTICALS was to receive payments when sales were made to Sinopharm. To date there have not been any sales generated from this agreement and no payment from Sinopharm have been made to LAM. Consequently EASTON PHARMACEUTICALS determined to terminate its relationship with Sinopharm.

On January 5, 2005, EASTON PHARMACEUTICALS entered into a provisional agreement with Finest Enterprises Limited and China Elegant Development Limited to acquire New World Kellerton, a pharmaceutical company based in Xinyang, China. The provisional agreement is non-binding and remains in effect until the execution of a definitive agreement. As of this date a definitive agreement has not been completed.

**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

EASTON PHARMACEUTICALS marketing plans related to licensed products, distribution agreements and products currently commercialized or in its pipeline are in the process of being revised and developed. EASTON PHARMACEUTICALS has received minimal orders for our product to date from the above distributors and will only receive payments to the extent that sales are made to the distributors.

It was the Company's intent to sell its wound care products to various hospitals, wound healing centers, physicians, nurses and other individuals through the Internet.

In late 2004 EASTON PHARMACEUTICALS applied to have its L.A.M. IPM Wound Gel approved for Medicare reimbursement. In 2005 the application as a drug was rejected by the FDA and was subsequently refused for Medicare reimbursement. As a result, patients could not claim to have the costs of the wound gel reimbursed, the cost of the product would be paid directly by the patient without any subsidy by Medicare, or other plans. This was considered a material setback to the Company's commercialization efforts as most of its products were considered expensive and unlikely to be paid for directly by patients. The Company subsequently made the decision to attempt to reformulate and alter the product to satisfy certain deficiencies illuminated by the Medicare and FDA review, and to wait the required 5 year period in order to be eligible to reapply for full Medicare reimbursement.

EASTON PHARMACEUTICALS was subsequently dependent on its sole remaining partnerships and hired consultants to take over the work from its founders and principles. The decision was subsequently made to acquire the VDM technology and other remaining assets of IXORA and of the VBMI.

There have been no revenues related to the L.A.M. IPM™ based products to date. In the third quarter of 2008 LAM's then board of directors decided to divest the L.A.M. IPM™ based assets and all products encompassing the L.A.M. IPM™ delivery system. Concurrently with the divesting of the L.A.M. IPM-based assets EASTON PHARMACEUTICALS acquired all of the remaining assets and knowhow of IXORA and VBMI, including the proprietary VDM delivery system and line of products and products in development (the "VDM and Ixora Products"). Completion of the acquisition of IXORA, VBMI and VDM Products was dependent upon the restructuring of LAM's capital structure, including debt (promissory notes) and common stock, among other conditions.

The acquisition of the assets and knowhow of VBMI and IXORA, including the VDM Products closed on 25<sup>th</sup> June, 2009 and 10<sup>th</sup> August, 2009 respectively, following completion of the conditions precedent to closing. The VDM Products are in various stages of development and commercialization, and we have not yet attempted to obtain clearance to market and sell products in the United States for any of the VDM Products nor attempted to market products that may not require approval. As a result, to date EASTON PHARMACEUTICALS has not generated material revenues from the sale of products and expects to incur losses until sufficient revenues are earned from the sale of first product to operate on a net profit basis. Management believes that the first product that will be available for sale will be "Viorra", to be marketed as a cosmetic gel to aid in the alleviation of Female Sexual Arousal Disorder "FSAD". EASTON PHARMACEUTICALS will conduct research, development and commercialization on a pipeline of products derived from the VDM technology.

On June 25, 2009, EASTON PHARMACEUTICALS purchased 100% of the Assets from Viorra Bio Medical Inc., a private Canadian Company, for a total of thirty six million (36,000,000) shares of EASTON PHARMACEUTICALS restricted common stock (the "Purchase Price" or the "Shares"). The shares were issued to non-U.S. persons and entities. These shares were issued pursuant to an exemption

**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

from registration requirements under Section 4(2) and exemptions provided under Regulation S ("Reg. S") of the Securities Act of 1933

On August 10, 2009 EASTON PHARMACEUTICALS purchased the remaining assets and know-how from Ixora Bio Medical Company Inc. and private shareholders for consideration of eight million (8,000,000) shares of EASTON PHARMACEUTICALS restricted common stock (the "Purchase Price" or the "Shares"). These shares were issued pursuant to an exemption from registration requirements under Section 4(2) and exemptions provided under Regulation S ("Reg. S") of the Securities Act of 1933. This acquisition resulted in EASTON PHARMACEUTICALS owning 100% of the assets of Ixora Inc. Immediately prior to the acquisition of the IXORA assets, EASTON PHARMACEUTICALS owned approximately 12% of the common stock of Ixora.

On September 4, 2009, a total of 14,258,220 (fourteen million two hundred and fifty eight thousand two hundred and twenty) common shares were issued pursuant to the conversion of convertible promissory notes dated June 11, 2006.

On September 12, 2013 EASTON PHARMACEUTICALS, Inc. closed on an agreement with a private Canadian company and individual to acquire a 50% ownership interest in an FSAD drug for the issuance of 10,000,000 restricted shares previously issued in escrow. This drug is a water soluble, non-irritating, gel that is applied directly to the external female genitalia and uses a transdermal delivery system to deliver Alprostadil (0.08%), also known as prostaglandin E1, into the tissue, primarily a mucous membrane. Alprostadil is a well-known vasodilator that has been shown to induce vulvar and clitoral engorgement, increase vulvar erythema and edema, which indicates increased blood flow to the genital area. In preliminary studies, the FSAD Drug gel has been shown to positively affect both the subjective and objective parameters of sexual arousal and pleasure in a dose dependent manner. Over the long term, this FSAD Drug offers the potential to naturally improve the previously reduced blood flow to the genital area and restore the ability of the tissue to become engorged with blood and increase lubricating secretions during sexual stimulation, leading to increased arousal and pleasure. Alprostadil, an off-patent therapeutic compound, which, when combined with the Glycotrans delivery system becomes subject to patent protection by virtue of its association with this proprietary delivery system. Any further research and development of this drug will require the consent and a mutual working relationship with the other 50% owner, a private Canadian Pharmaceutical Company.

In June of 2014 the Company advanced \$50,000 in Canadian currency to AMFIL Technologies. The agreement terms provided Easton with restricted shares in AMFIL with a 2 year option to acquire additional shares in AMFIL with a total advancement of \$80,000 in Canadian currency. The 2 year option was not exercised as the AMFIL stock price was 100% less than the then stock price of AMFIL technologies with no operating business. The shares were subsequently privately sold to pay a debt obligation and for cash in August of 2016. All affiliations with AMFIL were subsequently terminated.

**Recent Initiatives**

In 2018, Easton's board of directors decided to diversify the Company's activities and enter new market segments, in addition to its existing and new pharmaceutical business and initiatives, including real estate development and construction, food and beverage, gaming and cannabis, through a combination of strategic acquisitions and joint ventures.

**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

Easton established a Gaming Division, a Real Estate & Development Division, a Food & Beverage Division, as well as a Cannabis Division. The Company will focus in these areas going forward and it has put in place all the infrastructure necessary to grow its business.

The Company, through its Development Division, signed a service agreement during its third quarter of 2018 to provide construction services to a prominent developer, for the framing of 150 homes, just outside of Toronto, Ontario Canada. The contract is for \$2.6 million Canadian over the course of a few months. Revenues from the contract commenced in Q4 of 2018. Service revenue reported for the Quarter Ended June 30, 2019 was derived from this contract.

Easton is negotiating the acquisition of a company which owns land and a license for the development of a 540 room hotel/resort with a casino: this includes 1,000 slot machines and 50 tables games, a shopping center, health and wellness spa, conference facilities and 6 food and beverage outlets, among others. The casino approval has already been granted and the project is ready to be deployed. Easton is completing its agreements and it expects to have the transaction concluded in Q3 of 2019.

The Company has been in discussions with several service providers of gaming related services to charities with casino licenses operating throughout the United States. Letters of Intent have been signed and Easton expects to complete a transaction in Q3 of 2019. Easton had previously expected to have this completed in Q1 of 2019, however, due to changes in State legislation this has resulted in delays.

Easton entered into an agreement in October 2018 to acquire a fully operational video slot game, as well as bingo game content. The games are currently being developed and they will be placed in operating casinos leading to daily revenue for Easton. The games are expected to be placed in casinos in Q3 of 2019.

During Q4 of 2018, the Company signed an LOI to acquire 100% of a food processing company focused on baked products located in Toronto, Ontario Canada, with a 40,000 square foot production facility. The food processing company currently supplies major grocery and coffee chains, among others. This acquisition was completed on April 24, 2019 and Easton acquired all of the equipment, IP, recipes, customers list and inventory. Easton intends on expanding the existing business, as well as entering the lucrative cannabis edibles market. The Company has deployed sales people and has invested in further infrastructure to grow the business.

**1124123 Ontario Limited (o/a - Alliance Group) Acquisition**

In June of 2017, Easton executed an agreement with 1124123 Ontario Limited (o/a – Alliance Group). The agreement called for Easton to advance a total of \$1,300,000 Canadian Dollars in cash to acquire a 50% ownership interest in 45 acres of a 135 acre property located at 6017 Smith Blvd. Georgina Township, with 90 acres zoned M3 industrial and the remaining 45 acres zoned as agricultural. The agreement also calls for a 20% to 70% ownership interest in various businesses operating on the land, which includes a business to cultivate and grow medical / recreational marijuana for the Canadian market and an aggregate / soil business. All payments were forwarded with final payment made in October of 2017 completing all terms of the agreement. Once all terms were fulfilled, Alliance commenced the operation of the disposal of clean soil on the property, while it prepared the property for the aggregate portion of the business. In Q3 of 2018, the Town of Georgina stopped all operations on the property while they determined that the soil brought to the property was clean and did not contain any contaminants. No operations have been carried on since that

**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

time. Easton holds a \$1,000,000 Canadian Dollar mortgage on the property of which \$325,000 has been assigned to a third-party creditor as security on a loan. Alliance Group have retained legal counsel to address the issues with the Town in order to resume all operations.

At this time, Easton is considering other options available to it for the use of the property, currently permitted under its zoning, such as self-storage units or a possible residential development. The property has been appraised for over \$8 million Canadian.

**2315446 Ontario Inc. Acquisition (Cobourg Property)**

Easton entered into an agreement in Q2 of 2018 to acquire 100% of the shares of 2315446 Ontario Inc., which is a Canadian company that owns approximately 2.7 acres of land with an existing 10,000 square foot heritage mansion on the property, located in Cobourg, Ontario Canada. The Company was to pay cash to complete the acquisition, but was not able to do so at the time. The Company has since re-negotiated the terms of the purchase which was completed in Q1 of 2019. The Agreement calls for the issuance of restricted shares of Easton's common stock within 90 days of closing, which shares have not yet been issued and therefore the assets have not yet been reflected in the financial statements. Easton has commenced the development process on the property. The zoning allows for up-to 48 residential units on the property. Easton proposes to convert the existing mansion into 6 luxury units, which approval was previously granted, as well as build a new detached building containing additional condominium units which will be sold. Cobourg is approximately 1 hour east of Toronto and has a strong need for new residential development.

**iBliss Acquisition**

In late March 2017, Easton and the shareholders of iBliss Inc. executed an agreement for the purchase of 100% of iBliss by Easton Pharmaceuticals, Inc. In Q3 of 2017, Easton issued 218,000,000 shares to the iBliss subscribers. Easton had an obligation to pay the balance of the purchase price in cash, which it could not do and therefore the financial statements of iBliss have not been consolidated. Moreover, as a result of Easton's declining common stock price, the shares that were issued no longer represent the agreed upon valuation of iBliss Inc., therefore, the transaction terms were re-negotiated. iBliss is an established manufacturer of e-vapourizing liquids occupying approximately 20,000 square feet in Toronto, with sales throughout Canada, the United States and Europe.

**BAYER Sub-Distribution Agreement**

In November of 2017, Easton Pharmaceuticals through BMV Media SA de CV closed on a sub distribution agreement with multi-national pharmaceutical company, BAYER of Switzerland. The agreement was executed with BAYER's subsidiary company, Bayer Consumer Care for a sub-distribution agreement to sell Easton / BMV's woman's licensed diagnostic product VS-Sense in Mexico. The agreement called for a \$200,000 payment to Easton, which was received in December of 2017 and the payment of a 3% royalty on each product sold by BAYER. Product launch is expected in the 2nd quarter of 2019, with all decisions including product launch in the control of BAYER. Upon launch, Easton is to receive a further payment.



**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

**Mexico & Latin America – Licensed Diagnostic / Treatment Products**

In March of 2015, Easton Pharmaceuticals Inc. and BMV Medica S.A. de C.V. entered into an agreement which provided for profit sharing and ownership in certain patented Women's Health products related to the future sales of certain exclusive and patented Women's Health products and sales of certain Canadian-manufactured generic cancer drugs, in return for an investment by Easton into BMV. This investment into BMV was based upon a 50/50 net profit share on the revenues received from the Women's Health and generic cancer drug line, which was subsequently revised and a new agreement entered into in February 2016 whereby Easton owns 50% of the licensing rights.

**Patented Exclusive Women's Health Products from Common Sense LTD:**

**Vaginal Discharge Diagnostic Test and Amniotic Fluid Leak Test**

- Easton/BMV has recently secured exclusive rights for Mexico and all of Latin America (except Brazil) for a line of patented vaginal health diagnostic medical devices (VS-Sense) from an Israeli/US diagnostics company,- Common Sense LTD, of Cesarea, Israel. This diagnostic test is currently being sold Canada-wide (Shoppers Drug Marts), and across the US (at Walgreens and CVS pharmacies). Bayer AG, a global pharmaceutical giant has secured the exclusive rights to VS-Sense for the European Union and is launching in the United Kingdom in August, 2015, with a massive television and promotional campaign. Given the sizeable investment and faith that Bayer has in this product, Easton/BMV believe that VS-Sense presents an extremely lucrative opportunity in the Latin American market;
- In addition to the diagnostic test for vaginal health, Easton/BMV entered into a licensing agreement with a Swiss Company introduced by Common Sense to Easton/BMV to secure the rights to a natural Lactic Acid treatment for when the diagnostic test indicates the vaginitis is caused by bacteria (roughly two-thirds of cases). This natural lactic acid gel vaginal cream causes the vaginal pH to change enough to kill the offending bacterial organisms. The remaining one third of cases diagnosed are yeast based and Easton/BMV will launch under their own brand the current treatment (clotrimazol cream) for these infections. In this way, Easton/BMV will have the triangle model: diagnostic component as well as offering treatments for all causes of the vaginitis: one diagnostic test, followed by two treatment options depending on what the diagnostic test results show after initial use;
- As mentioned above, BMV acquired the rights for a natural treatment for bacterial vaginosis and is already approved in Europe and Mexico, which will afford gynecologist's the opportunity to sell, in office, both the diagnostic and treatment in Latin America. This represents a potentially large revenue-producing option for both the gynecologists and Easton/BMV. In November of 2016, Easton / BMV entered into an agreement with Gedeon Richter Plc of Hungary to sub-license its lactic acid gel treatment. The product was named "Gynofit" and was officially launched in Mexico in March of 2017.
- In addition to the diagnostic test for vaginal health, Easton / BMV secured additional rights to all products from Common Sense including (VS-Sense, AL-Sense) for a \$300,000 USD payment in March of 2017. Easton / BMV have secured the rights for all of Latin America (except Brazil) for a second point-of-care diagnostic device; unique in the time, cost, and ease-of-use for late-pregnancy women who experience wetness in their undergarments and are not sure if it is urine or amniotic fluid, quite a common occurrence, and one of the major causes of OB/GYN visits by women in late-stage pregnancy. This diagnostic device called AL-Sense provides a differential diagnosis between urine and amniotic fluid. BMV has a tremendous opportunity with this amniotic fluid leak diagnostic test in that there is an unmet need with no competition. Furthermore this Amniotic Fluid Leak test is part of the NHS's late-pregnancy protocol for all women.

**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

- This Amniotic fluid test, AmnioSense (AL-Sense) is intended for pregnant women, mainly in late-stage pregnancy to enable them to detect the difference between an amniotic fluid leak (AmnioSense (AL-Sense)) which would necessitate a doctor's visit (as labour has started) and a simple urine leak. The test may also be used by High Risk pregnant women to monitor for Amniotic Fluid leaks beginning at earlier stages of pregnancy. This test is a state-of-the-art diagnostic test which is in the form of a panty liner, and undergoes a simple color change if the wetness experienced by the pregnant woman caused by an amniotic fluid leak. The relatively low cost and ease of use is expected to quickly become the test of choice for both women at home and in hospital use.
- This test has been endorsed by NHS (National Health Service) in Britain as part of the NICE report (National Institute for Health and Care Excellence) which indicates that the device can reliably exclude amniotic fluid leak as a cause of vaginal wetness in pregnancy, avoiding the need for a speculum examination and its associated discomforts. Using the device in the community could prevent unnecessary referrals to secondary care antenatal day units or maternity triage services for speculum examinations, releasing clinical time. Based on cost modelling, using the test offers significant cost savings
- Other countries where AmnioSense (AL-Sense) test is being sold include UK, Italy, Japan, China, Israel, Australia and other countries. The product is currently being registered in the USA and Canada
- Easton/BMV believe with a Marketing budget of \$500,000 sales of the suite of exclusive Women's Diagnostic and Treatment products could reach US\$8-12 MM annually within three years.

**Generic Cancer Drugs**

- Easton/BMV has secured exclusive rights for a line of Canadian-manufactured generic cancer drugs from Biolyse Corporation of St. Catharines, Ontario Canada, beginning with four of the most commonly used chemotherapy agents namely paclitaxel, methotrexate, 5-fluorouracil and docetaxel. Biolyse is adding to these a further 33 injectable cancer and antibiotic drugs within the coming years, all of which will be available to Easton/BMV exclusively for the region;

Generic Cancer Drugs: The cancer drugs: Biolyse Pharma Corporation the manufacturer of these drugs initially entered into an exclusive distribution agreement with BMV Medica, and BMV in turn then entered into a 50/50 profit split with Easton Pharmaceuticals for the full line of Biolyse-manufactured drugs beginning with Paclitaxel and Docetaxel two of the most-commonly prescribed cancer (oncology) drugs in use today, prescribed for breast, lung, colon and several other cancers. Both drugs are generic with manufacturers from the US, Canada, Mexico, Europe and India vying for a total market of several Billion dollars for these two drugs.

Easton/BMV's market is Latin America, where, starting in Mexico, Canadian-manufactured drugs have an advantage over the Asian-origin drugs, because of NAFTA (North American Free Trade Agreement), allowing Canadian manufacturers to enter into the lucrative national tenders. In addition Canadian-manufactured cancer drugs also have a perceived advantage in quality over the Asian-manufactured counterparts. Easton/BMV have licensed the exclusive rights for the full line of Biolyse-manufactured drugs expected to reach in excess of over 30 drug offerings in the coming five years.

Easton/BMV have received the drug dossiers from Biolyse Pharma and are working with a local Mexican Company: Ackerman Pharma/Bio MS to submit for Marketing Authorization in Mexico for paclitaxel and docetaxel. These approvals are expected to be granted over the next 6 months.

Once these approvals are in place, Easton/BMV expect to begin sales in Mexico very quickly and believes these two cancer drugs will reach revenues of several million dollars over the next three years through sales into both the private and government contract buyers.

**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

In parallel with the Mexican initiative, several countries in Latin America do not require extensive regulatory dossier submissions, in order to purchase these Canadian-manufactured drugs. Once funding is secured Easton/BMV will immediately pursue Sales & Distribution agreements with distributors in Latin American countries where this simplified regulatory pathway is in place.

Easton/BMV believe with a basic marketing program sales of paclitaxel and docetaxel could reach US\$10 MM within three years

**Drug Delivery Technology**

The drugs transdermal delivery technology is a safe, novel and proprietary drug delivery platform that has been developed based on more than 30 years of research by various individuals to address many of the needs in the multi billion dollar drug delivery segment of the pharmaceutical market. The proprietary system used only in the FSAD Drug consists of a water based, complex polymer matrix, which includes methoxypolyethyleneglycol, hydroxyethylcellulose and carboxymethylcellulose.

Included with the 50% ownership interest with the purchase of the FEMLIFE Drug are the following patents or patent pendings filed at that time:

- (i) Canadian Patent Application Number CA 2,591,203;
- (ii) U.S. Patent Application No. 11/010,154;  
Patent Cooperation Treaty Application Number PCT/IB2005/003672 (publication number W02006/061689; and
- (iii) European Patent Application Number EP 2005810583

On November 5, 2013 EASTON PHARMACEUTICALS, Inc. acquired an initial 10% ownership interest in a Cancer Treatment Drug called “XILIVE”, with an exclusive option to purchase the remaining ownership interest exercisable at any point in time over the next 12 month time period. Should EASTON PHARMACEUTICALS provide funding towards any testing or clinical trials, these expenditures will be included and put towards acquiring additional ownership in the drug. “XILIVE” has not undergone any independent clinical trials, but was previously administered by the current majority owners on individuals outside of the U.S. suffering from various forms of advanced stage cancer with others on a list of prospective candidates. Initial feedback was promising enough to allow EASTON PHARMACEUTICALS to acquire an initial 10% ownership interest through a cash payment. It is the Company’s intent to enter into some type of feasibility, safety and efficacy tests once patent pendings are filed. Any type of North American trials may depend on the involvement or the approval of the FDA in the United States and Health Canada in Canada. The Company is currently contemplating forming alliances with certain other companies who have adequate resources and knowledge towards such trials in the jurisdiction of the United States and Canada. Other avenues being seriously contemplated are to have “XILIVE” utilized in various other countries such as Mexico, Germany, Italy and other countries where regulations are deemed less stringent for the use of experimental early stage drugs for the treatment of certain cancers.

In June of 2013 the Company disclosed its intentions to enter into the medical marijuana industry. The Company subsequently signed various Letters of Intent and Agreement in both the United States and Canada including with Vodis Pharmaceuticals of Vancouver, BC, but subsequently executed and entered into an agreement in June of 2014 with a company called MDRM Group Canada for an exclusive option to purchase up to 50% of a private Canadian medical marijuana grower (Aero Farms) who has received a letter to build from Health Canada to obtain a medical marijuana growers license under Canada’s MMPR system as it was called at that time, which went into effect on April 1<sup>st</sup> 2014. The private MMJ company (Aero Farms) is presently building out its facilities prior to a final inspection towards a national growers

**Easton Pharmaceuticals, Inc.**

For the Quarter Ending June 30, 2019

**Prepared by management without audit**

license for medical marijuana. MDRM Canada has subsequently been removed allowing for Easton to negotiate directly with the private medical marijuana company (Aero Farms), but no agreements have yet been executed after several discussions. The letter of intent is now null and void.

On July 1<sup>st</sup> 2014 the Company executed an agreement with a North Carolina based company (Medicated Markets International) who maintained ownership rights to a medical marijuana grow-op located within the state of California. The Agreement called for a due diligence period which subsequently closed in January of 2015. The Agreement was amended on January 17, 2015. Medicated Markets and its principles have assisted and provided the Company with executed agreements within the medical marijuana sector in Canada and therefore Easton released shares.

In November of 2014, the Company closed on an acquisition with Digital Shock media for the Vaporizer business operating under <http://www.420.com> and <http://www.ecigmarkets.com> for cash paid by Easton.

In June of 2014 the Company advanced \$50,000 in Canadian currency to AMFIL Technologies. The agreement terms provided Easton with restricted shares in AMFIL with a 2 year option to acquire additional shares in AMFIL with a total advancement of \$80,000 in Canadian currency. The 2 year option was not exercised as the AMFIL stock price was 100% less than the then stock price of AMFIL technologies with no operating business. The shares were subsequently privately sold to pay a debt obligation and for cash in August of 2016. All affiliations with AMFIL were subsequently terminated.

On March 22, 2015 the Company attained the rights from Common Sense Ltd., an Israeli based company for the exclusive distribution rights of a patented woman's diagnostic product known as the VS-Sense Diagnostic Product for the country of Mexico which is currently being sold in the United States, Canada and soon Europe. The rights are shared jointly with BMV Medica S.A de C.V. as per an agreement signed between the parties. Subsequently, Easton and BMV executed an LOI to acquire the rights to the remaining Latin American territories. Easton has paid approximately \$850,000 USD towards licensing rights of various products and expenses since March of 2015.

## **Patents and Trademarks**

Prior to the then Board of Directors decision to abandon and suspend any further research and development or commercialization efforts for products based on the EASTON PHARMACEUTICALS, Inc. (formerly LAM) L.A.M. IPM™ technology, in the fall of 2008, EASTON PHARMACEUTICALS, Inc. (formerly LAM) owned fifteen U.S. patents, nine foreign patents, five U.S. patent applications and numerous international patent applications designating over 100 foreign countries with claims relating to our sustained release delivery matrix system, systems containing drug preparations, uses of the systems for various treatment therapies and addiction therapeutic program. The patents were to expire between 2015 and 2018.

## **6. Issuer's Facilities**

In June of 2017, Easton executed an agreement with 1124123 Ontario Limited (o/a – Alliance Group). The agreement called for Easton to advance a total of \$1,300,000 Canadian Dollars in cash to acquire a 50% ownership interest in 45 acres of a 135 acre property located at 6017 Smith Blvd. Georgina Township, with 90 acres zoned M3 industrial and the remaining 45 acres zoned as agricultural. The agreement also calls for

## Easton Pharmaceuticals Inc. Financial Statements

### Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

#### Prepared by management without audit

a 20% to 70% ownership interest in various businesses operating on the land, which includes a business to cultivate and grow medical / recreational marijuana for the Canadian market and an aggregate / soil business. All payments were forwarded with final payment made in October of 2017 completing all terms of the agreement. Once all terms were fulfilled, Alliance commenced the operation of the disposal of clean soil on the property, while it prepared the property for the aggregate portion of the business. In Q3 of 2018, the Town of Georgina stopped all operations on the property while they determined that the soil brought to the property was clean and did not contain any contaminants. No operations have been carried on since that time. Easton holds a \$1,000,000 Canadian Dollar mortgage on the property of which \$325,000 has been assigned to a third-party creditor as security on a loan. Alliance Group have retained legal counsel to address the issues with the Town in order to resume all operations.

At this time, Easton is considering other options available to it for the use of the property, currently permitted under its zoning, such as self-storage units or a possible residential development. The property has been appraised for over \$8 million Canadian. The property consists of vacant land with a 2 storey dwelling used for the property maintenance. The overall condition of the property is good.

Easton is operating from 111 Brockhouse Road, Toronto, Ontario, Canada, which comprises of a 40,000 + square foot building housing Easton's offices, as well as the production facility of its food processing company.

### 7. Officers, Directors, and Control Persons

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Evan Karras</u>	<u>Officer/Director</u>	<u>111 Brockhouse Rd. Toronto, Ontario M8W 2W8 Canada</u>	<u>60,000,000</u>	<u>Common</u>	<u>4.5</u>	_____
<u>Vince Demasi</u>	<u>Director</u>	<u>111 Brockhouse Rd. Toronto, Ontario M8W 2W8 Canada</u>	<u>0</u>	<u>N/A</u>	<u>0</u>	_____
_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____

### 8. Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

## Easton Pharmaceuticals Inc. Financial Statements

---

### Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

#### Prepared by management without audit

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

No.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No.

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None.

### 9. Third Party Providers

#### Securities Counsel

Name: Williams Robinson Eilers  
Firm: William Robinson Eilers, Esq.  
Address 1: 149 South Lexington Avenue, Asheville, North Carolina 28801  
Phone: 786-273-9152  
Email: wreilers@eilerslawgroup.com

#### Accountant or Auditor

Name: Alexander Murphy  
Firm: Alexander Murphy Chartered Professional Accountant  
Address 1: 1613 Brookridge Drive, Burlington, Ontario L7P 4S9  
Phone: 905-635-6977  
Email: alex@murphyco.ca

#### Investor Relations Consultant

## Easton Pharmaceuticals Inc. Financial Statements

### Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

Prepared by management without audit

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

#### Other Service Providers

Provide the name of any other service provider(s), including, counsel, advisor(s) or consultant(s) **that assisted, advised, prepared or provided information with respect to this disclosure statement**, or provided assistance or services to the issuer during the reporting period.

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Nature of Services: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

#### 10. Issuer Certification

I, Evan Karras, certify that:

1. I have reviewed this annual disclosure statement of Easton Pharmaceuticals, Inc. for the quarter ended June 30, 2019;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

By:	<i>/s/ Evan Karras</i>	
Name:	Evan Karras	
Title:	CEO / Director	
Date:	June 30, 2019	

## Easton Pharmaceuticals Inc. Financial Statements

---

### Easton Pharmaceuticals, Inc.

For the Quarter Ending June 30, 2019

Prepared by management without audit

I, Vince Demasi, certify that:

1. I have reviewed this annual disclosure statement of Easton Pharmaceuticals, Inc. for the quarter ended June 30, 2019;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

By:	<i>/s/ Vince Demasi</i>	
Name:	Vince Demasi	
Title:	Director	
Date:	June 30, 2019	